Biotech company Exscientia brings Series C to $100M
March 5, 2021
BlackRock has backed AI drug developer Exscientia, bringing the UK-based startup's Series C to $100 million. The proceeds of the round will be used to fund clinical trials and expand its drug development pipeline. Exscientia uses artificial intelligence to analyze data at the drug discovery stage, which in turn shortens the time it takes to develop new treatments.